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n INTRODUCTION
The improved prognosis of HIV under the ef-fective antiretroviral regimens increased the 
interest for other rampant comorbidities responsi-
Cardiovascular disease (CVD) in the HIV population ac-
counts for a large proportion of morbidity and mortality 
and, with the increased life expectancy, the burden of 
CVD is expected to rise. Inflammation, immune dys-
function, side effects of HIV medications, high preva-
lence of other risk factors are the likely pathogenic mech-
anisms for accelerated atherosclerosis. We aimed to eval-
uate the diagnostic yield of a cardiovascular multimo-
dality diagnostic work-up in a contemporary cohort of 
HIV-infected patients. From November 2017 to October 
2019, HIV infected patients were screened in a cardio-
vascular diagnostic work-up program including clinical 
history, physical examination, arterial blood pressure 
measurement, 12-lead ECG, and Transthoracic Echocar-
diogram (TTE). Advanced non-invasive cardiovascular 
imaging tests, like Coronary Computed Tomography 
Angiography (CCTA), stress-echocardiography, Cardiac 
Magnetic Resonance (CMR), were performed in patients 
with suspicion of chronic coronary syndrome (CCS) or 
non-ischemic heart disease (NIHD). 117 HIV-infected 
consecutive patients underwent this cardiovascular di-
SUMMARY
agnostic work-up and were included in our study. Fif-
ty-two patients (45%) had evidence of CVD. Of them, 22 
presented Coronary Artery Disease (CAD), whereas 47 
cases showed NIHD. In 17 cases both conditions were 
present. Among patients with CAD, 8 showed critical 
coronary stenosis; among them, 5 were treated with per-
cutaneous coronary intervention, 2 with Aorto-Coro-
nary By-Pass Grafting (CABG), and one with medical 
therapy. Hypertension and diabetes were significantly 
associated with the development of CVD (respectively 
p<0.001 and p<0.05), while current smoking (p<0.02) 
and hypertension (p<0.007) were positively associated 
to CAD. A comprehensive cardiovascular diagnostic 
work-up including advanced multimodality diagnostic 
imaging modalities led to early detection of CVD in 
nearly half of an HIV population with immediate inter-
ventions required in 6.8% of them, and aggressive pre-
vention treatment started in the remaining HIV patients.
Keywords: HIV, cardiology, multimodality imaging, 
cardiovascular disease, diagnostic work-up.
ble for a rising share of the morbidity and mortal-
ity observed in these patients [1]. Additionally, in 
observational studies of HIV patients, the propor-
tion of total deaths due to Cardiovascular Disease 
(CVD) ranged from 6.5% to 15%, with HIV infec-
tion alone conferring a 61% increased risk com-
pared to uninfected individuals of comparable 
age and sex [1, 2]. 
The pathophysiology of CVD in HIV is complex 
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and multifactorial. The interplay of several items 
is involved, such as inflammation, autoimmune 
mechanisms, direct HIV-induced myocardial dam-
age, side effects of HIV medications, nutritional 
factors, accelerated atherosclerosis and increased 
burden of traditional cardiovascular risk factors 
[3-8].
HIV-infected patients can develop both Coronary 
Artery Disease (CAD), due to accelerated athero-
sclerosis, and Non-Ischemic Heart Disease (NIHD), 
since the HIV infection may involve the pericardi-
um, myocardium, cardiac valves and pulmonary 
circulation [9-24]. 
The clinical manifestations of CVD in HIV-infect-
ed patients differ from the general population, 
often presenting as unexpected and severe events 
suddenly interrupting a silent clinical history [25]. 
A crucial issue is the lack of applicability of con-
ventional risk scores, leaving healthcare provid-
ers without reliable decision-making instruments 
to select the appropriate diagnostic work-up and 
tailored treatment [26, 27]. Thanks to the recent 
advances in technology, non-invasive multimo-
dality cardiovascular imaging could be a power-
ful tool in providing new insights into the patho-
genesis of CVD seen in the HIV-positive popula-
tion and in identifying patients at-risk. 
We aimed to evaluate the prevalence of CVD 
through a cardiovascular multimodality diagnos-
tic investigation in a cohort of HIV-infected pa-
tients. We assumed that a thorough diagnostic 
evaluation would allow to early detection of car-
diovascular diseases in a large number of patients, 
with considerable impact on therapeutic and fol-
low-up strategies.
n PATIENTS AND METHODS 
Patients selection
This study is a cross-sectional study conducted at 
the Infectious Diseases outpatient clinic of our ter-
tiary care university hospital. From November 
2017 to October 2019, HIV infected patients aged 
≥40 years old in follow-up with at least one cardi-
ovascular risk factor such as smoke, hyperten-
sion, dyslipidaemia, diabetes were consecutively 
Figure 1 - Diagnostic flow chart 
of the cardiovascular screen-
ing algorithm.
TTE, transthoracic echocardio-
gram; CAD, coronary artery di-
sease; CMR, cardiac magnetic 
resonance; CCS, chronic coro-
nary syndrome; MI, myocardial 









Figure 1 - Diagnostic flow chart of the cardiovascular screening algorithm. 
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enrolled and addressed to the cardiovascular di-
agnostic work-up program (Diagnostic Flow-
chart, Figure 1). All patients provided written in-
formed consent. We excluded from the study pa-
tients with a known cardiac disease or those who 
have not given informed consent. 
The viro-immunological profile of each patient 
has been examined, focusing on HIV duration, 
duration of antiretroviral therapy (ART) use, 
CD4+ nadir, zenith viremia, and the presence of 
detectable viremia. Likewise, we searched for oth-
er co-infections (HBsAg positivity, anti-HBc posi-
tivity, HCV co-infection) and recorded the antiret-
roviral therapy administered. The ongoing three 
drugs ART regimens at the time of the cardiologic 
visit were divided by the anchor drugs as follows: 
reverse transcriptase-inhibitor (NNRTI), protease 
inhibitor (PI), and integrase strand transfer inhib-
itor (INSTI). Where this definition was not appli-
cable (three-drugs regimen with 1 or 3 nucleo-
side/nucleotide reverse transcriptase inhibitors 
[NtRTI/NsRTI], not boosted PI, PI monotherapy 
and more or less than three drugs) we classified as 
“others”. The panel of laboratory tests included 
general blood tests like full blood count, glyce-
mia, HbA1c, renal and hepatic function, and lipid 
profile were collected within 3 months before the 
cardiology visit.
Cardiovascular diagnostic work-up
HIV-infected patients enrolled in the study were 
referred to the outpatient Cardiology clinic for a 
comprehensive cardiology evaluation with the 
following routine data collection: 
	– Clinical history and physical examination.
	– Arterial blood pressure measurement.
	– 12-lead ECG.
	– Transthoracic echocardiogram (TTE).
Clinical characteristics, laboratory test results and 
pharmacological therapy data were collected to 
assess the Framingham Risk Score, calculated 
with the software elaborated by CHIP (Centre for 
Health & Infectious Disease Research) of the Co-
penaghen University. 
According to the diagnostic flow-chart (Figure 1), 
patients presenting clinical, ECG, and/or echo-
cardiographic features of unstable angina or with 
evidence of previous silent myocardial infarction 
were admitted to hospital to perform an invasive 
coronary angiogram (ICA). Patients with clinical, 
ECG, and/or echocardiographic features sugges-
tive for a chronic coronary syndrome (CCS) un-
derwent a second-level non-invasive imaging test 
(coronary computed tomography angiography 
(CCTA) and/or stress echocardiography/stress 
cardiac MRI) [28]. Whether critical CAD was sus-
pected (coronary stenosis >50% at the CCTA ex-
amination and/or positive stress echocardio-
gram/MRI), hospital admission was scheduled to 
perform ICA. Patients with evidence of cardiomy-
opathy, moderate-to-severe valvular disease not 
properly assessable by TTE, or with pericardial 
effusion underwent Cardiac Magnetic Resonance. 
Counseling for lifestyle modification and smok-
ing cessation was offered to all patients with 
modifiable cardiovascular risk factors. The base-
line therapy of all patients was carefully evaluat-
ed and modified, if necessary, based on the cur-
rent European guidelines on CVD prevention [29] 
and after careful verification of any drug interac-
tions with the ongoing antiretroviral therapy, 
through consultation of the reference tabs drafted 
by the University of Liverpool (https://www.
hiv-druginteractions.org/).
Patients with evidence of cardiovascular disease, 
intended as any clinical condition involving heart, 
great vessels and coronary arteries requiring 
treatment changes were included in a tailored fol-
low-up program. 
CAD was defined as the evidence of ≥1 coro-
nary plaques at the CCTA or ICA examination. 
Critical CAD was defined as coronary stenosis 
≥75% in ≥1 vessels (≥50% in the left main coro-
nary artery) at the ICA. Liberal use of intracor-
onary physiologic measurements was encour-
aged when required.
Statistical analysis
Continuous variables were expressed as mean 
(M) ± standard deviation (SD) when normally 
distributed or as median and interquartile range 
(IQR) when not normally distributed. Categorical 
variables were expressed as number (N) and per-
centage (%). The Student 2-sample t-test and 
Mann-Whitney-Wilcoxon rank-sum test were 
used to compare the differences between groups 
for continuous variables. X2 and Fisher exact test 
were used for categorical variables where appro-
priate. All statistical analyses were performed us-
ing a standard software package (Stata, version 
14.0; StataCorp). Two-sided probability values 
were considered significant at p<0.05.
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n RESULTS
Basic features of the investigated population
One hundred and fifty HIV-infected patients old-
er than 40 years of age have been referred for car-
diovascular diagnostic work-up. Of those, 117 
patients met the inclusion criteria. 
The baseline characteristics of the investigated 
population are summarized in Table 1.
Of the patients evaluated, 91 were males (77.7%) 
and 26 females (22.3%). The mean age was 56 
years. The most frequent transmission route re-
sulted the sexual one: heterosexuals in 50.4% of 
cases, and omosexuals in 36.8% (males who have 
sex with males (MSM). The 7.7% were intrave-
nous drug user, and the 5.1% of patients were il-
licit drugs abusers, or alcohol.
The viro-immunologic characteristics at baseline 
of the population are listed in Table 2. The median 
of years of positivity to HIV was 21 (range 0-34), 
while the median of ART treatment was 19 years 
[IQR 11-22]. The 91.2 % of patiens had no detecta-
ble viremia (<20 copies/mL) in plasma. The co-in-
fections recorded were 9.8% HBV, 18.6% HCV 
and 23.5% syphilis. The 14.7% of patients had a 
previous AIDS event, and 5.9% had an acute ret-
roviral infection. As for ART, the Integrase Strand 
Transfer Inhibitors (INSTI) were the most used 
anchor drug (53%). As shown in Table 3, 50% of 
patients had less than two comorbidities, 32.3% 
had between 3 and 4, and 17.7% had more than 
four comorbidities. Table 4 lists the cardiovascu-
lar (CV) risk factors, baseline therapy, arterial 
blood pressure, and ECG interpretation. Among 
the patients, the 53% had dyslipidemia, the 47% 
were current smokers, the 37% suffered from hy-
Table 1 - Demographic characteristics.
Demographic characteristics, n=117 (%)















South-Est Asiatic 1 (0.9%)
MSM, male who has sex with male; IVDU, intravenous drug user.
Table 2 - Viro-immunologic characteristics.
Viro-immunologic characteristics n=117
Duration HIV (years, median, IQR) 21, 13-26
Duration ART use 
(years, median, IQR)
19, 11-22
Nadir CD4+ (cells/µL), median, IQR 251, 159-332
Zenith viremia (copie/mL), 
median, IQR
60000, 7000-207000
Drug abuse 6 (5.1%)
Alcohol Abuse 6 (5.1%)
Detectable viremia 9 (7.7%)
HBsAg positivity 10 (8.5%)
anti-HBc positivity 32 (27.3%)
HCV co-infection 19 (16.2%)
Syphilis 24 (20.5%)
Previous AIDS event 15 (12.8%)
Acute retroviral infection 6 (5.1%)
Single tablet regimen 51 (43.5%)












ART, antiretroviral therapy; PI, protease inhibitors; NRTI, Nucleoside 
analogue reverse-transcriptase inhibitors; INSTI, Integrase strand 
transfer inhibitors; NNRTI, non-nucleoside analogue reverse-tran-
scriptase inhibitors; IQR, Interquartile Range.
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pertension, and the 9% were diabetic. Of note, 
29.1% of them presented a single CV risk factors, 
whereas the 27.3% presented ≥3 CV risk factors.
Results of the cardiovascular diagnostic work-up
Of the 117 patients evaluated in the study, one pa-
tient showed ECG and TTE findings of previous 
silent myocardial infarction, and another one had 
features of unstable angina; both were hospital-
ized with high priority to perform an ICA. 
Non-invasive second level imaging test was per-
formed in 27 patients with suspected CCS. CCTA 
was performed in 24 patients and stress-echocar-
diography or cardiac MRI with dipyridamole was 
performed in 3 patients. Nine of them underwent 
ICA in the suspicion of critical CAD. Nine pa-
tients with evidence of NIHD underwent CMR.
Prevalence of cardiac disease 
Of the 117 patients evaluated in the screening, 52 
(45%) had evidence of cardiovascular disease (Ta-
ble 5). Of them, 22 presented CAD, whereas 47 
cases showed a NIHD. In 17 cases both conditions 
were present. 
ICA confirmed a critical CAD in 8 patients: 5 of 
them were treated with percutaneous coronary 
interventions, 2 with aorto-coronary by-pass 
(CABG), one presented a chronic coronary occlu-
sion with non-viable myocardium and remained 
on medical treatment. Three patients undergoing 
ICA and 11 patients assessed non-invasively with 
CCTA showed a non-critical CAD requiring med-
ical therapy and follow-up. Among the 8 patients 
with critical CAD, 4 were asymptomatic, 2 report-
ed atypical chest pain, and 2 complained of exer-
tional dyspnoea.
The NIHD group was broader and more hetero-
geneous. Hypertensive cardiomyopathy was the 
Table 4 - Results from cardiology visit.
Cardiovascular risk factors n=117 
Smoke (current) 55 (47%)




Family history of CAD 27 (23.1%)
1 CV risk factor 34 (29.1%)
2 CV risk factors 45 (38.5%)
≥3 CV risk factors 32 (27.3%)










Beta Blockers 10 (8.5%)
Arterial blood pressure
SBP (mmHg) 135, 121-143.5
DBP (mmHg) 80, 75-89
MAP(mmHg) 97, 90-106
ECG
Sinus rythm 116 (99.1%)
Atrial fibrillation 1 (0.09%)
Heart rate (bpm) 74±13
CAD, coronary artery disease; SBP, systolic blood pressure; DBP, di-
astolic blood pressure; MAP, mean arterial pressure; ACE-I, angioten-
sin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers. 
Table 5 - Results of the diagnostic work-up: prevalence 
of the cardiovascular disease.
Prevalence of CVD n=117
CVD 52 (44%)
Coronary artery disease 22 (18.8%)
Critical coronary artery disease 8 (6.8%)
Non-critical CAD 14 (11.9%)
Non-ischemic heart disease 47 (40.1%)
Hypertensive cardiomyopathy 21 (17.9%)
Aortic disease 9 (7.7%)
Pericardial effusion 5 (4.3%)
Valvular disease (moderate-to-severe degree) 14 (11.9%)
Atrial fibrillation 1 (0.8%)
Hypertrophic cardiomyopathy 2 (1.7%)
Pulmonary hypertension 5 (4.3%)
LV systolic dysfunction 3 (2.6%)
CVD, cardiovascular disease; CAD, coronary artery disease; LV, left 
ventricle.
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most frequent condition, with 21 cases diagnosed 
(18%). The 12% of patients showed valvular dis-
ease of moderate or severe degree and the 8% ex-
pressed thoracic aortic dilatation (>40 mm). Peri-
cardial effusion, pulmonary hypertension, and 
left ventricle (LV) systolic dysfunction were also 
found in some patients (Table 5, Figure 2). Two 
cases of hypertrophic cardiomyopathy and one 
patient with atrial fibrillation were also detected.
Risk of CVD
As reported in Table 6, patients with CVD were 
older than those without CVD (60.7±8.8 vs 
53.4±7.3; p<0.001). Hypertension and diabetes 
were significantly associated with the develop-
ment of CVD (p<0.001 and p<0.05, respectively), 
whereas smoking and dyslipidaemia did not 
show a significant association. Patients with high-
er levels of blood pressure at the visit and of glu-
cose at the laboratory exams had an increased risk 
of CVD. The duration of HIV infection, the pres-
ence of detectable viremia and the impact of the 
last therapy on the CVD prevalence were not sig-
nificantly associated with the development of 
CVD.
Risk of CAD 
As for the CVD group, patients with CAD were 
older with a mean age of 60.2±7.0 years, com-
pared to the 56.4±9.1 shown by the patients with-
out CAD (p=0,049, Table 7). In the development of 
CAD, gender demonstrated to be statistically sig-
nificant as all patients with CAD were male 








Figure 2 - Non-ischemic heart disease in the population examined. 
 
LV, left ventricle; CM, cardiomyopathy; AF, atrial fibrillation. 
 
 






Age (years) 60.7±8.8 53.4±7.3 <0.001
Males 43 (82.7%) 37 (74%) 0.286
Females 9 (17.3%) 13 (26%) 0.286
Detectable viremia 
(<20 copies/mL)



























Smoke (current) 25 (48%) 20 (40%) 0.362
Smoke (previous) 13 (25.5%) 15 (30%) 0.613
Hypertension 27 (53%) 10 (20%) 0.001
Diabetes 8 (15.7%) 2 (4%) 0.049
Dyslipidemia 30 (58.8%) 23 (46%) 0.197
SBP (mmHg) 140±17 128±14 <0.001
DBP (mmHg) 83±11 78±10 0.02
MAP (mmHg) 100±19 92±13 0.02






Glucose(mg/dL) 109±37 94±14 0.01
Col Tot (mg/dL) 196±37 201±35 0.5
LDL (mg/dL) 117±40 119±36 0.84
HDL (mg/dL) 53±23 48±16 0.2
Tg (mg/dL) 168±117 173±167 0.87
Lp(a) 285±385 312±411 0.71
NT-proBNP 91±111 77±85 0.49
hs-CRP (mg/L) 90±111 77±85 0.52
CVD, cardiovascular disease; ART, antiretroviral therapy; PI, pro-
tease inhibitors; NRTI, nucleoside analogue reverse-transcriptase 
inhibitors; INSTI, integrase strand transfer inhibitors; NNRTI, non-
nucleoside analogue reverse-transcriptase inhibitors; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; MAP, mean arterial 
pressure; HbA1c, Glycated hemoglobin; Lp(a), lipoprotein(a); NT-
proBNP, N-terminal prohormone of brain natriuretic peptide; LDL, 
low-density lipoprotein; Tg, triglycerides; hs-CRP, high sensitivity 
C-reactive protein.
Figure 2 - Non-ischemic heart disease in the popula-
tion examined.
LV, left ventricle; CM, cardiomyopathy; AF, atrial fibrillation.
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ated to CAD (66.7% vs 38.0%; p=0.02), as well as 
hypertension (62% vs 30% p=0.007). Although the 
blood glucose and HbA1c level were higher in 
CAD group than in the group without CAD, the 
prevalence of known DM among patients with 
CAD was higher but not statistically significant 
when compared with the group without CAD 
(p=0,115). The lipid profile did not differ signifi-
cantly in the two groups, with patients affected by 
CAD presenting even lower total cholesterol, 
LDL, triglycerides, and higher HDL levels com-
pared to patients without CAD (Table 7). 
The Framingham score was unable to perform a 
correct risk stratification of CAD in our popula-
tion (Table 8).
n DISCUSSION
The HIV infection alone appears to confer a 61% 
increased risk for cardiovascular disease com-
pared with the general population [2, 30]. Fur-
thermore, the prolongation of life expectancy in 
the past two decades obtained with the introduc-
tion of cART means that HIV-infected people 
have been affected by more comorbidities and 
age-related non-communicable diseases. The 
pathogenic mechanisms underlying CVD in 
HIV-infected patients are still debated and risk 
stratification tools to predict the risk in this popu-
lation are lacking [31]. The current study shows a 
surprisingly high prevalence of CVD in HIV-in-
fected patients >40 years old with at least one CV 
risk factor. Of the 117 patients enrolled in our 
study, 45% showed a cardiovascular disease. Of 
note, 10% of the cohort examined required hospi-
talization to perform ICA in the suspicion of criti-
cal CAD, which was confirmed in 8 patients out 
of 11.
Importantly, none of these patients presented 
with typical chest pain, and half of them were 
completely asymptomatic. It is important to per-
morf a comprehensive cardiac evaluation in all 






Age (years) 60.2±7 56.4±9.1 0.049
Males 22 (100%) 59 (73.7%) 0.007
Females 0 (0%) 22 (27%) 0.007
Detectable  
viremia




Duration ART use 
(years)
<10 3 (13.6%) 19 (23.7%) 0.363















Smoke (current) 14 (63.6%) 31 (38.7%) 0.02
Smoke (previous) 3 (13.6%) 25 (31.3%) 0.122
Hypertension 13 (59.1%) 24 (30%) 0.007
Diabetes 4 (18.2%) 6 (7.5%) 0.115
Dyslipidemia 10 (45.5%) 43 (53.8%) 0.617
SBP (mmHg) 144.7±18.6 131.5±15.7 0.003
DBP (mmHg) 87±11 79±10 0.006
MAP (mmHg) 106±13 93±19 0.007
White blood cells 
(10^9/L)
6955±2218 6421±1943 0.278




Col Tot (mg/dL) 189±34 201±36 0.187
LDL (mg/dL) 115±35 119±39 0.731
HDL (mg/dL) 54±13 52±21 0.088
Tg (mg/dL) 174±117 170±149 0.894
Lp(a) 267±278 306±380 0.67
ntProBNP 80.5±109 85.4±97 0.8437
hsPCR (mg/L) 78.3±110 85.4±97 0.777
CVD, cardiovascular disease; ART, antiretroviral therapy; PI, protease 
inhibitors; NRTI, nucleoside analogue reverse-transcriptase inhibitors; 
INSTI, integrase strand transfer inhibitors; NNRTI, non-nucleoside 
analogue reverse-transcriptase inhibitors; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; MAP, mean arterial pressure; HbA1c, 
glycated hemoglobin; Lp(a), lipoprotein(a); NT-proBNP, N-terminal 
prohormone of brain natriuretic peptide; LDL, low-density lipoprotein; 
Tg, triglycerides; hs-CRP, high sensitivity C-reactive protein.
Table 8 - Framingham risk score of patients with CAD 
vs. patients with no CAD.
Framingham risk score CAD no-CAD p-value
<10% 17.7% 40.6% 0.161
10-20% 29.4% 26.7%
>20% 53% 32.4%
CAD, coronary artery disease
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HIV patients at increased cardiovascular risk, 
even if they do not complain of typical symptoms 
for CAD, to unmask silent but potentially 
life-threatening cardiac conditions. 
The algorithm that we applied for the diagnosis 
of CCS followed the current European guidelines 
recommending either non-invasive anatomical 
imaging using CCTA or functional imaging as the 
initial test to rule out or establish the diagnosis of 
CCS in high-risk patients [28]. In non-HIV pa-
tients, CCTA demonstrated strong prognostic val-
ue in patients with suspected CAD. The Prospec-
tive Studies PROMISE and SCOT-HEART have 
shown the incremental value of CCTA over the 
conventional practice in investigating patients 
with suspected angina [32]. Moreover, technolog-
ical developments have also led to a marked re-
duction in radiation dose. Imaging with most re-
cent dedicated CT scanners can be performed 
with low (3-5 mSv) and ultra-low (<1 mSv) radia-
tion doses [33]. Non-invasive functional imaging 
such as stress echocardiography or stress CMR is 
an alternative to CCTA in the diagnosis of myo-
cardial ischemia, and it is recommended if coro-
nary CTA has shown CAD of uncertain functional 
significance or is not diagnostic. Although exer-
cise-ECG was the most widely used provocative 
test in clinical practice, recent guidelines have 
downgraded its indication due to its low sensitiv-
ity, moderate specificity, and frequent equivocal 
results. For these reasons, exercise ECG was 
avoided in a population at high risk of CV events 
as the HIV one due to its low accuracy. In contrast, 
non-invasive advanced imaging modalities such 
as CCTA were extensively applied in patients 
with suspicion of CCS. The benefit is not only to 
diagnose flow-limiting CAD but also to detect 
non-obstructive CAD and thus to identify pa-
tients who could benefit from aggressive preven-
tive medications (i.e., aspirin or statins) and life-
style interventions. This allowed us to limit inva-
sive angiography to a small minority of patients, 
with angiography confirming in most of them se-
vere coronary artery disease. 
Non-ischemic heart disease was frequent in our 
population, with an overall prevalence of 40.1%, 
and included a heterogeneous cluster of condi-
tions, with hypertensive heart disease being the 
most frequent. 
Similarly to the general population, hypertension 
appears to play an essential role in the develop-
ment of CVD also for our HIV patients. It is of 
clinical relevance that a Systolic Blood Pressure 
(SBP) mean value overcoming slightly the target 
for treatment established by the EACS guidelines 
(SBP<140), was found both in the group with evi-
dence of CVD (140±17; p<0,001) and in the sub-
group with CAD (144±18; p=0,007) [34]. As for 
Diastolic Blood Pressure (DBP), the mean values 
remained under the target for both groups 
(DBP<90). There is no tailored guideline for hy-
pertension treatment in HIV patients, forcing 
physicians to adopt the same approach applied to 
the general population. However, this data sug-
gests that BP targets may be lowered in HIV pa-
tients such as in other high-risk patients such as 
those with diabetes, starting lifestyle modifica-
tions and drug interventions as soon as BP ex-
ceeds the upper range of normal.
In our study, patients with CVD, and particularly 
those with CAD, showed an increased prevalence 
of glucose metabolism disorders. Conversely, we 
did not find any significant association between 
CVD and the alteration of the lipid profile. In fact, 
despite a high prevalence of dyslipidaemia in the 
whole study group (51.9%), higher (58,8%) among 
those who had CVD, these findings were not sup-
ported by statistical significance. 
Our study is in line with previous reports con-
cerning the current smoking habit, which ap-
peared strongly associated with the development 
of CAD. These results confirmed the importance 
of counseling for quitting the smoking habit in 
this high-risk group of patients.
The population we examined was well treated for 
their HIV infection, presenting a detectable 
viremia (>20 copies/µL) only in 9.6% of patients. 
The same prevalence was found in the group with 
CVD, regardless of the time of infection and ART 
treatment. This data is similar to other studies, 
where it has already been clarified the emerging 
role of inflammation and immune activation as 
drivers of comorbidities, despite an optimal con-
trol of viremia and CD4+ T cells level [35, 36]. 
The Framingham score was unable to stratify the 
cardiovascular risk in our population, confirm-
ing, as previous studies stated, the need for a spe-
cific cardiovascular risk score tailored for HIV 
patients [37, 38]. 
The principal limitation of this study regards the 
small dimension of the investigation as well as 
the lack of longitudinal follow-up data, which 
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could evaluate the significant benefit in terms of 
survival and reduction of major adverse cardio-
vascular events caused by the application of the 
diagnostic and therapeutic algorithms applied in 
this study. Moreover, a match with an HIV-nega-
tive control group is welcome to evaluate differ-
ences in the prevalence of CVD in comparable 
cohorts.
n CONCLUSION
A comprehensive cardiovascular diagnostic work-
up, including new advanced multimodality diag-
nostic imaging modalities, demonstrated to be a 
useful tool to ensure early diagnosis and better 
management of CVD in HIV patients. 
Our study proved that a standardized cardiology 
evaluation is necessary, particularly in a subset of 
patients in which CVD does not manifest with its 
traditional signs and symptoms. The early recog-
nition of cardiovascular disease allows prompt 
management of symptoms and, through the strict 
control of cardiovascular risk factors, we can 
modify the natural course of cardiovascular dis-
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